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cer resistance protein (BCRP), are expressed on the luminal surface of capillaries in the CNS and transport drugs
out of the endothelium back into the blood against the concentration gradient. Survival motor neuron (SMN)
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it SMN degradation in the CNS of SMAmice with a combination of bortezomib and the ABC transporter inhibitor
tariquidar. In cultured cells we show that bortezomib is a substrate of P-gp. Mass spectrometry analysis demon-
strated that intraperitoneal co-administration of tariquidar increased the CNS penetrance of bortezomib, and re-
duced proteasome activity in the brain and spinal cord. This correlated with increased SMN protein levels and
improved survival and motor function of SMA mice. These ﬁndings show that CNS penetrance of treatment for
this neurological disorder can be improved by inhibiting drug efﬂux at the blood–brain barrier.
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Pharmacotherapy for neurodegenerative disorders is hampered by
the inability of most small molecules to cross the blood–brain barrier
(BBB) and the blood spinal cord barrier (BSCB). Three main cell types,
the endothelial cells, pericytes, and astrocytes form the BBB and BSCB
and protect the central nervous system (CNS) by restricting diffusion
of many solutes into the cerebrospinal ﬂuid. This is achieved through a
combination of tight junctions formed by the endothelial cells, a lack
of pinocytotic activity, and efﬂux transporters. The predominant efﬂux
transporters, P-glycoprotein (P-gp, ABCB1) and breast cancer resistance
protein (BCRP, ABCG2), are members of the ATP-binding cassette (ABC)
class. They are expressed on the apical surface of endothelial cell and
function to intercept drugs entering the CNS capillary cells andding 35, Bethesda, MD 20892,
ect.com).
. This is an open access article undertransport them against their concentration gradient back into the
blood (Schinkel et al., 1994, 1996; Rao et al., 1999; Cherry et al.,
2013). The BBB and BSCB are fully formed (Saunders et al., 2012) and
P-gp and BCRP transporters are correctly localized well before birth
(Daood et al., 2008). While there are some differences between the
BBB and BSCB including lower protein levels of tight junction markers
and increases to permeability there are no signiﬁcant differences in P-
gp levels (Bartanusz et al., 2011).
Spinal muscular atrophy (SMA) is a motor neuron disorder caused
by deletions and other mutations of the highly conserved survival of
motor neuron-1 gene (SMN1) with retention of the nearly identical
paralog, SMN2. A promising approach to treating SMA is to increase
levels of SMN protein by reducing its degradation through the ubiquitin
proteasome system (Lefebvre et al., 1995;McAndrew et al., 1997; Kwon
et al., 2013). We have previously shown that inhibition of the protea-
some by the inhibitor bortezomib increases SMN protein levels in cul-
tured cells and in peripheral tissues of SMA mice. Long term
bortezomib treatment resulted in an improvement in motor function
in SMA mice compared with vehicle treated animals; however survival
was unaffected (Kwon et al., 2011). Pre-clinical studies have shown that
bortezomib is unable to penetrate into the CNS, impeding its use forthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Rumpold et al., 2007; Lu et al., 2010). To overcome bortezomib's low
biodistribution in the CNS, we hypothesized that pre-treatment with
an ABC transporter inhibitor would prevent bortezomib's efﬂux at the
blood–brain and –spinal cord barriers.
In this study we used overexpress cell lines, genetic mouse models,
and systemic administration of an inhibitor to demonstrate that
bortezomib is a substrate of P-gp. Using mass spectrometry we were
able to detect bortezomib in the CNS of SMA model mice co-
administered with a P-gp inhibitor tariquidar. SMN levels were also in-
creased in the CNS of model mice treated with both drugs. Tariquidar
and bortezomib treated mice also lived longer and had improved
motor function compared with tariquidar-alone, bortezomib-alone,
and vehicle treated counterparts. These data suggest that P-gp inhibi-
tion increases the CNS bioavailability of a proteasome inhibitor, which
is of particular interest in the development of therapeutics for neurolog-
ical disorders.
2. Results
2.1. Bortezomib is transported by P-gp
In order to verify that bortezomib is transported by P-gp and not by
other transporters (O'Connor et al., 2013) we used MCF-7 and HEK293
cells that express P-gp, BCRP, or no drug efﬂux transporters and tested
bortezomib's transport. MCF-7 cells do not express high levels of P-gp
or BCRP at baseline; however selection with ﬂavopiridol increases
BCRP expression (Robey et al., 2001) and selection with etoposide in-
creases P-gp levels (Schneider et al., 1994). We therefore generated
MCF-7 cells that expressed P-gp or BRCP using these selection process-
es. Since we were interested in the basal activity of the proteasome in
the treated cells we tested several different cell lysate protein concen-
trations to ﬁnd an appropriate concentration at which chymotrypsin-
like activity of the endogenous proteasome was measurable
(Supplemental Fig. 1a). The chymotrypsin-like activity of the endoge-
nous proteasome of 70 μg of cell lysate was well above the residual ac-
tivity seen with no substrate or no lysate negative controls, but less
than the maximal amount seen when excess puriﬁed proteasome was
tested. The chymotrypsin-like activity of the proteasome of the drug
naive cells in the presence of bortezomib and tariquidar was similar to
bortezomib alone (n = 6, p N 0.05) (Fig. 1a). However, MCF-7 cells
that had been selected to express P-gp showed further reduction ofFig. 1. Bortezomib is transported by P-gp1, but not by BCRP in culturedMCF-7 cells. Cells drug s
(1 μL per 1 mL) for 15 min then with bortezomib (0.5 μM) or PBS (1 μL per 1 mL) for 30 min. T
examining the cleavage of the ﬂuorogenic peptide Suc-LLVY-AMC (a,b,c) when it was added to
SEM,*p b 0.05, n = 6.chymotrypsin-like activity of the proteasome with tariquidar pre-
treatment (1 μM, 15 min) before bortezomib treatment (0.5 μM,
30 min) (n = 6, p b 0.05) (Fig. 1b). However, pre-treatment with
tariquidar did not signiﬁcantly increase the inhibition of theproteasome
of the BCRP overexpressing cells when compared with bortezomib
alone treatment (n = 6, p N 0.05) (Fig. 1c).
HEK293 cells do not typically express P-gp (Robey et al., 2011);
bortezomib (0.5 μM, 30 min) inhibited the chymotrypsin-like activity
of the proteasome (n = 6, p b 0.01) and there was no additive effect
when the cells were pretreated with tariquidar (n = 6, p N 0.05)
(Supplemental Fig. 2a). Cells that stably express P-gp showed increased
inhibition to the chymotrypsin-like activity of the proteasome when
treated with tariquidar (15 min, 1 μM) before bortezomib treatment
(0.5 μM, 30 min) (n = 6, p b 0.05) (Supplemental Fig. 2b). Tariquidar
treatment alone does not inhibit the chymotrypsin-like activity of the
proteasome in either the MCF-7 cells (Fig. 1a, b, c) or the HEK cells
(Supplemental Fig. 2c). Together, these data indicated that bortezomib
was a substrate of P-gp, but not of BRCP.
2.2. Bortezomib levels and proteasome inhibition are enhanced in spinal
cord of P-gp1a/b BCRP knockout mice compared with control mice
We veriﬁed that bortezomib was transported by P-gp in vivo by
treating P-gp1a/b/BCRP triple knockout mice (FVB.129P2-Abcb1a-
tm1Bor:Acb1btm1Bor:Abcg2tm1Ahs N7) or the parental strain (FVB) mice
with a single dose of bortezomib (Velcade) by intraperitoneal (i.p.) in-
jection (0.15 mg/kg). Mice carry two P-gp genes, unlike humans, and
both genes must be knocked down to prevent drug extrusion from the
cytoplasmic membrane (Croop et al., 1989). Tariquidar is a known in-
hibitor of both P-gp and BCRP (Bauer et al., 2013) and these triple
knockout mice most closely mimic the anticipated effects of tariquidar
treatment.
We measured the levels of bortezomib in the CNS by liquid chroma-
tography–tandem mass spectrometry (LCMS/MS) and observed that
bortezomib in the spinal cord was 3.2 fold higher 1 h post injection in
the P-gp1a/b:BCRP knockout mouse spinal cords (257.9 ± 79.1 ng/mg
tissue) compared with the spinal cords of the parental strain mice
(38.7 ± 0.9 ng/mg tissue) (p b 0.01) (Fig. 2a). Additionally, the
chymotrypsin-like activity of the proteasomewas decreased in the spinal
cord lysates 1 h post-injection of the bortezomib- treated P-gp1a/b/BCRP
knockout mice compared with the bortezomib-treated parental strain
mice (p b 0.05) (Fig. 2b). A single dose of bortezomib (0.15 mg/kg) didelected for P-gp, BCRP, or no drug treatment were treatedwith tariquidar (1 μM) or DMSO
he cells were lysed and the chymotrypsin-like activity of the proteasome was assessed by
the cell lysates. Values represent chymotrypsin-like activity relative to vehicle control ±
Fig. 2. Bortezomib penetrates the BBB of PGP1a/b:BCRP knockout mice, but not the parental strain control mice (FVB). Mice at P12 were injected with bortezomib (0.15 mg/kg) and
sacriﬁced 1 h later. The spinal cords were removed and bortezomib levels were analyzed with LCMS/MS (a). The chymotrypsin-like activity of the endogenous proteasome in the
spinal cords was assessed by analyzing the cleavage of the ﬂuorogenic peptide Suc-LLVY-AMC (b) when it was added to spinal cord lysate. Values represent, respectively, bortezomib
concentration or chymotrypsin-like activity relative to wild type control ± SEM,*p b 0.01.
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chymotrypsin-like catalytic activity PSMB5 (Supplemental Fig. 3).
2.3. Bortezomib levels in SMAmouse CNS increase and proteasome activity
is inhibited with co-administration of an ABC transporter inhibitor
Having shown that bortezomib was a substrate of P-gp in cultured
cells and in mice we next sought to determine whether the ABC trans-
porter inhibitor tariquidar could increase the CNS penetrance of
bortezomib and slow SMN degradation in SMA model mice. SMA pups
(hSMN2:Δ7SMN:smn−/−) were treated by i.p. injections of
bortezomib (0.15 mg/kg) starting at post-natal day 4 (P4) and
continued every other day until P8. At P8 the dose of bortezomib was
decreased to 0.075 mg/kg, due to diarrhea observed in preliminaryFig. 3. Bortezomib penetrates the BBB and BSCB when mice are pre-treated with tariquidar. M
before bortezomib (0.15 mg/kg–0.075 mg/kg) or vehicle (Ringer's solution, 1 μL/g) i.p. inje
concentration using LCMS/MS (a). The chymotrypsin-like activity of the proteasome in the b
(b) when it was added to the brain lysate. Values represent, respectively, bortezomib conc
SEM,*p b 0.01.studies (outlined in Kwon et al., 2011) from extended treatment with
the higher dose of bortezomib, and the mice were subsequently
treated every other day until P12. In addition, pups were administered
(99% pure by high performance liquid chromatography) tariquidar
(i.p., 6.5 or 13 mg/kg) 15 min before bortezomib administration. The
bortezomib and tariquidar combination treatment paradigm used here
did not alter the typical weight gain of control mice compared to
tariquidar-only treatment and untreated controls (Supplemental Fig. 4),
and no early deaths were seen.
Micewere sacriﬁced at P12, and levels of bortezomib in the brains of
bortezomib-only and bortezomib and tariquidar-treated mice were
measured by LCMS/MS. Bortezomib levels in the brain were nearly un-
detectable in bortezomib-only treated mice (106 ± 28 ng/mg tissue),
but increased 4.5 fold when bortezomib was co-administered withice at P4 were given tariquidar (6.5 or 13 mg/kg) or vehicle (100% DMSO, 1 μL/g) 15 min
ction every other day and sacriﬁced at P12. The brains were analyzed for bortezomib
rains was assessed by examining the cleavage of the ﬂuorogenic peptide Suc-LLVY-AMC
entration or chymotrypsin-like activity relative to bortezomib-only treated control ±
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creases in bortezomib penetrance occurred in spinal cord tissue.
However, the small tissue volumes of the spinal cord from late stage
SMA disease mice led to higher levels of variability, and a statistically
signiﬁcant difference was not observed in the spinal cord samples
(Supplemental Fig. 5). In addition, the chymotrypsin-like activity of
the proteasome in the brain was reduced in bortezomib and
tariquidar-treated animals compared with bortezomib-only treated an-
imals (p b 0.01) (Fig. 3b).
2.4. Bortezomib increases SMN protein levels in the SMA mouse CNS when
paired with a P-gp inhibitor
Since we observed increased penetrance of bortezomib into the CNS
with tariquidar pre-treatment, we investigated whether SMN levels in-
creased as well. We reported previously that levels of SMN increased in
peripheral tissue in bortezomib-treatedmice, but no changewas seen in
CNS tissue (Kwon et al., 2011). Co-administration of two different doses
of tariquidar (6.5 and 13 mg/kg) with bortezomib increased SMN pro-
tein levels in the brain, but the increase in SMN protein only reachedFig. 4. Bortezomib with tariquidar pre-treatment increases SMN protein levels in the CNS. Mic
15 min before bortezomib (0.15 mg/kg) or vehicle (Ringer's solution, μL/g) i.p. injection ev
protein levels in the brain (b), while the SMN increase with 6.5 mg/kg tariquidar (a) was n
lysates from these tissues were isolated to examine SMN protein levels. The ratio of SMN to a
SEM. *p b 0.05, n = 6.statistical signiﬁcance with the 13 mg/kg dose of tariquidar (n = 6,
p b 0.05) (Fig. 4a,b). Similar SMN protein increases were seen in spinal
cord tissue although the small tissue volumes from late stage SMA dis-
ease mice led to higher levels of variability, and a statistically signiﬁcant
difference was not observed (Supplemental Fig. 6).
2.5. Bortezomib enhances motor function in SMA model mice when paired
with a P-gp inhibitor
Since there were increases to SMN protein levels in the CNS we
asked whether the CNS penetrance would also improve the functional
beneﬁt of bortezomib. SMA mice were treated as described above, but
with treatment continuing until mice reached pre-speciﬁed conditions
for euthanasia (30% weight loss or inability to right after 30 s). The
SMA mice begin to show difﬁculty with righting at day 10 leading to
an inability to right within 30 s by day 14 with the median age of
death 13. days (Le et al., 2005). We detected an improvement in the
righting times of mice treated with bortezomib and tariquidar over
bortezomib alone (n= 10, p b 0.05 starting at day 8) (Fig. 5a). Combin-
ing bortezomibwith tariquidar pre-treatment further extended survivale were treated with tariquidar (6.5 mg/kg or 13 mg/kg) or vehicle (100% DMSO, 1 μL/g)
ery other day starting at P4 and sacriﬁced at P12. 13 mg/kg tariquidar increased SMN
ot signiﬁcantly different from bortezomib alone. Brain tissue was removed and protein
ctin protein levels was determined by a densitometry analysis. Values represent mean ±
Fig. 5. CNS penetrance of bortezomib with tariquidar pre-treatment improves motor
function and increases survival over bortezomib treatment alone. Mice at P4 were
treated with tariquidar (13 mg/kg) or vehicle (100% DMSO, 1 μL/g) 15 min before
bortezomib (0.15 mg/kg–0.075 mg/kg) or vehicle (Ringer's solution, 1 μL/g) i.p. injection
every other day. Righting times of SMA mice improved when treated with bortezomib
and tariquidar compared to bortezomib treatment alone (a). CNS penetrance of
bortezomib confers a survival beneﬁt. Mice at P4 were treated with tariquidar
(13 mg/kg) or vehicle (DMSO) 15 min before bortezomib (0.15 mg/kg–0.075 mg/kg) or
vehicle (Ringer's solution) injection every other day. Mouse survival was increased by
one and a half days with bortezomib and tariquidar treatment compared to bortezomib
alone. Kaplan Meier survival curve p b 0.05, n = 13.
122 E. Foran et al. / Neurobiology of Disease 88 (2016) 118–124by 1.5 day compared with bortezomib treatment alone (n = 13,
p b 0.05) (Fig. 5b).
3. Discussion
The BBB and BSCB restrict the ability of drugs to reach their intended
site of action in the CNS and thus present amajor challenge to the treat-
ment of neurological disorders. This has prompted interest in develop-
ing novel drug delivery strategies to improve therapeutic access to the
CNS (Pardridge, 2012). In this studywe aimed to show that (i) P-gp im-
pacted the efﬁcacy of bortezomib in our model systems and that (ii)
inhibiting P-gp improved the CNS delivery and efﬁcacy of a pharmaceu-
tical agent in amodel of motor neuron disease.We showed that protea-
some function is inhibited when P-gpwas either deleted or inhibited in
the presence of bortezomib. Importantly, bortezomib inhibition of the
proteasome increased steady-state SMN protein levels in the CNS
when P-gp was inhibited. Additionally, motor function and survival
were enhanced with SMN stabilization in the CNS.
It has previously been reported that bortezomib is transported by
P-gp (Nakamura et al., 2007; Rumpold et al., 2007; Lu et al., 2010;
O'Connor et al., 2013), primarily in the context of cancer multidrug
resistance (Jung et al., 2004). Interestingly a silent polymorphism in
P-gp, MDR1 C3435T, confers increased latency to relapse and higher
bortezomib efﬁcacy in human multiple myeloma (Buda et al., 2009,
2010). While BCRP has also been implicated in bortezomib efﬂux (Gil
et al., 2007; Wiberg et al., 2009) it has been stated by others that P-gp
is the primary transporter responsible for bortezomib efﬂux(O'Connor et al., 2013).We used the P-gp and BCRP inhibitor tariquidar
to prevent bortezomib efﬂux (Kannan et al., 2011). While the contribu-
tion of other efﬂux pumps appears unlikely it has also been postulated
that the decrease in efﬁcacy of bortezomib in patients is due to other
mechanisms such as upregulation of PSMB5, a subunit of the protea-
some (Lu et al., 2008, 2009). Using genetic models and pharmacological
agents we conﬁrm that bortezomib is indeed a substrate of P-gp, inde-
pendent of PSMB5 expression.
We showed previously that bortezomib stabilizes SMN protein
levels in peripheral tissue (Kwon et al., 2011). We showed here that
bortezomib is a potent proteasome inhibitor in the CNS when allowed
to cross the BBB. Bortezomib activity in the CNS stabilizes SMN protein
levels and improves SMA disease manifestations in mice. It has been
established that increasing SMN protein levels through induction of
the SMN2 gene or altering splicing improves SMA pathology in mouse
models (Foust et al., 2010; Hua et al., 2011; Cherry et al., 2013). Stabiliz-
ing SMN protein by blocking protein degradation in peripheral tissue
improvesmotor function of SMNmice, but does not extend survival, re-
inforcing the critical role of SMN in the CNS.We demonstrated here that
bortezomib was normally excluded from the CNS and that increasing
bortezomib levels in the CNS had positive effects on SMA pathology in
mice. However, the survival beneﬁt of bortezomib was less robust
than that seen with other compounds that increased SMN to similar
levels. One possibility is that off-target toxicity associated with
bortezomib prevented full effects of the SMN stabilization. Indeed, it
has been shown in humanpatients that bortezomib can cause peripher-
al neuropathy (Argyriou et al., 2008). It has been determined that
bortezomib also inhibits HtrA2/Omi, an ATP-dependent serine protease
in mitochondria which protects neurons from undergoing apoptosis
(Arastu-Kapur et al., 2011), and this likely accounts for the peripheral
neuropathy. Importantly, increasing speciﬁcity dramatically decreased
proteasome inhibitor cytotoxicity in cultured cells (Screen et al.,
2010). The next-generation proteasome inhibitors currently undergo-
ing clinical consideration can achieve stronger inhibition of
chymotrypsin-like activity of the proteasome in vivo and do not inhibit
HtrA2.
Recently, it was shown that the amyotrophic lateral sclerosis (ALS)
drug riluzole has increased efﬁcacy in an animal model of familial ALS
when co-administered with an ABC transporter inhibitor elacridar
(Jablonski et al., 2014). Additionally, co-administration of tariquidar
with the anti-seizure drug pentobarbital improves anti-epileptic activi-
ty in previously drug resistant rats (Brandt et al., 2006). Any therapy
under development intended to be active in the CNS must be able to
traverse the BBB and BSCB and not be transported by P-gp. There are
no current FDA-approved proteasome inhibitors reported to be CNS
permeable. The drug efﬂux transporters represent a formidable obstacle
when developing new therapies for neuromuscular and neurodegener-
ative disorders. Our results show that pharmacological inhibition of
P-gp can enhance CNS penetrance of bortezomib. Inhibition of P-gp by
tariquidar has been demonstrated in humans with PET imaging, using
IV administration (Bauer et al., 2015; Kreisl et al., 2015). Our study
and the study with the ALS model reported by Jablonski et al. demon-
strate that co-administration of P-gp inhibitors with CNS treatments
can improve their efﬁcacy.
4. Materials and methods
4.1. Mice
Studies were approved by the National Institute of Neurological
Diseases and Stroke Animal Care and Use Committee and done in accor-
dance with the National Institutes of Health Guide for the Care and Use
of Laboratory Animals. Transgenic SMA mice on the FVB background
(hSMN2/Δ7SMN/mSmn−/−) were purchased from Jackson Laborato-
ries. The animals were genotyped using polymerase chain reaction on
tail DNA using two sets of primers against mouse smn and beta-
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(Kernochan et al., 2005).
Pgp-1a/b and BCRP knock out mice (FVB.129P2-Abcb1atm1Bor
Abcb1btm1BorAbcg2tm1Ahs) were a kind gift from Dr. Robert Innis, NIMH.
The animals were genotyped using polymerase chain reaction on ear
punch tissues to ensure that they lacked both isoforms of P-gp1 and
BCRP.
For biochemical studies, the mice were anesthetized with
isoﬂuorane and sacriﬁced by cervical dislocation. Spinal cords, brains,
and livers were dissected, ﬂash-frozen in liquid nitrogen, and stored at
−80 °C.
For survival studies, litters were maintained and kept with the
mother until euthanasia with no supplementation. Mice that lost 30%
of their body weight and were unable to right themselves after 30 s
were euthanized as mandated by the NINDS ACUC committee.4.2. Drug treatment
Bortezomib was dissolved in sterile Ringer's solution to a concentra-
tion of 0.15 μg/μL or 0.075 μg/μL. Pups at postnatal day 4 (P4) and at day
6 (P6) were administered 1 μL of 0.15 μg/μL bortezomib per gram (for a
concentration of 0.15 mg/kg) intraperitoneally. We had found that
0.15 mg/kg was the highest tolerated in neonatal mice (Kwon et al.,
2011). From P8 to P12 pups were injected every other day with 1 μL
of 0.075 μg/μL bortezomib per gram (for a concentration of
0.075 mg/kg). Control animals received equal volumes of Ringer's sa-
line. 99% pure by HPLC tariquidarwas dissolved in 100% DMSO to a con-
centration of 6.5 μg/μL or 13 μg/μL. Pups at P4 were administered 1 μL of
tariquidar per gram every other day for a total concentration of
6.5 mg/kg or 13 mg/kg in a manner similar to bortezomib. Tomaximize
the dose of bortezomib crossing the BBB, mice were given tariquidar
15 min before bortezomib. Control animals received equal volumes of
DMSO.4.3. Motor function analysis
For one-timemeasures, pupswereweighed and tested for their abil-
ity to right themselves. Righting timewas deﬁned as the average of four
trials of the time required for a pup to turn over after being placed on its
back (maximum 30 s) (Cherry et al., 2013).4.4. Protein extraction and quantiﬁcation
Spinal cords were homogenized and incubated in 500 μL of lysis
buffer (0.1% NP-40 and 0.5% sodium deoxycholate) for 15 min on ice,
and the collected lysates were sonicated for 3 pulses of 10 s before
another 15 min incubation on ice. Supernatants were collected after
15 min centrifugation at 14,000 g at 4 °C and stored at−80 °C. Protein
concentrations were determined by the Bradford Protein Assay kit
(Bio-Rad) according to the manufacturer's protocol.4.5. Western blotting
Protein lysates (50 μg) were run and separated on a 10% SDS-PAGE
gel electrophoresis gel and transferred to a PVDF membrane.
These membranes were then probed with a mouse anti-SMN antibody
(BD Transduction Laboratories, diluted 1:1000), and a mouse anti-β-
actin antibody (Sigma-Aldrich, diluted 1:10,000) or a mouse anti-B-tu-
bulin (Sigma-Aldrich, 1:1000)) and followed by incubation with goat
HRP-conjugated anti-mouse secondary antibody. Blots were developed
using Clarity ECL (BioRad). AllWestern blot images were collected with
Chemidoc (Bio-Rad).4.6. In vitro transport
HEK293 cells stably transfected with either an empty vector or P-gp
were cultured in DMEM +10%FBS and geneticin (Life Technologies,
1:1000). The cells were plated in 6-well plates, 2 × 106 cells per well.
The cells were treated with tariquidar (15 min, 1 μM) then treated
with bortezomib (30 min, 0.5 μM). The cells were then collected in
500 μL lysis buffer (0.1% NP-40 and 0.5% sodium deoxycholate) for
15 min on ice. Protein concentrations were determined by the Bradford
Protein Assay kit (Bio-Rad) according to the manufacturer's protocol.
4.7. Proteasome assay
Chymotrytic-like activity of the proteasomewasmeasured bymixing
(70 μg) tissue or cell homogenate with 50 μM ﬂuorogenic peptide Suc-
LLVY-AMC (succinyl-Leu-Leu-Val-Tyr-7-amino-4-methylcoumarin)
(Enzo Life Sciences, Farmingdale, NY) in a ﬁnal volume of 100 μL. The re-
action buffer consisted of 50 mM Tris–HCl (pH 7.8), 20 mM KCl, 5 mM
MgCl2, and 1 mM dithiothreitol. The mixture was incubated at 37 °C
for 30 min, and the released ﬂuorogenic AMC was measured at 360-
nm excitation and 460-nm emission. Epoxomicin (or MG132)-insensi-
tive activity was subtracted from the ﬁnal activity calculation. Substrate
only or lysate only controls with no residual ﬂuorescence signal and in-
cubation with excess puriﬁed proteasome with multifold higher levels
of signal were included in every assay.
4.8. Liquid chromatography tandem mass spectrometry (LCMS/MS)
Flash frozen spinal cord tissue samples were mixed with PBS
(pH 7.2, 1:1 ratio) and homogenized with a pestle-type homogenizer.
The homogenate was treated with 2 volumes of acetonitrile to precipi-
tate the proteins, and the supernatant was analyzed by LCMS/MS.
Samples were created for calibration and quality control with a
working dilution of bortezomib inwarfarin at 50 times the ﬁnal concen-
tration, and this was serially diluted to make the standard samples.
These samples were diluted 31-fold into blank tissue extract and proc-
essed as above.
The signal was optimized for bortezomib by electrospray negative
ionization (ESI) mode. A MS2 targeted SIM scan was used to optimize
the precursor ion, and a product ion analysis was used to identify the
best fragment for analysis and to optimize the collision energy.
Sampleswere analyzedwith anABI3000mass spectrometer coupled
with a Shimadzu HPLC and a Sil-HTc chilled autosampler, all controlled
by Analyst software (ABI). After separation on a C18 reverse phaseHPLC
column (Agilent,Waters, or equivalent)mobile phase Awas 0.1% formic
acid in water and mobile phase B was 0.1% formic acid in acetonitrile.
4.9. Statistics
All analysis was carried out by investigatorswhowere blinded to the
drug conditions or mouse genotype. All statistics were carried out using
the GraphPad Prism software package (version 6; GraphPad Software)
and compared with either two-tailed Student's t-test or one-way
ANOVA followed by the Newman–Keuls multiple comparison post hoc
tests. p ≤ 0.05 was considered signiﬁcant.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2016.01.008.
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